Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies
Sarepta stock crashed Tuesday after a patient who received its approved gene therapy, Elevidys, died due to acute liver failure. The post Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies appeared first on Investor's Business Daily.
Sarepta stock crashed Tuesday after a patient who received its approved gene therapy, Elevidys, died due to acute liver failure.
The post Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
